University of California Health Remote (Home) Monitoring Evaluation
Evaluation of a University of California-wide Quality Improvement Effort to Improve Blood Pressure Control Using Remote (Home) Monitoring
Study Overview
Status
Conditions
Detailed Description
Hypertension is an important modifiable risk factor for numerous adverse health outcomes including cardiovascular and kidney disease. In 2017, about 45.3% of US adults had hypertension or were taking antihypertensive medications (1).
Hypertension has historically been diagnosed and treated using office-based blood pressure measurements, however blood pressure may differ when measured in the office compared to the home setting. Because of this discrepancy, and an extensive body of evidence supporting remote monitoring, national guidelines for hypertension management now recommend that all persons with hypertension participate in remote (home) monitoring. (2)
This study sets out to evaluate a University of California-wide (Davis, San Francisco, and Los Angeles) quality improvement initiative to increase remote (home) blood pressure monitoring and improve blood pressure control for persons with hypertension. Participants at each site will be randomized to one of two types of remote monitoring: integrated versus manual. Participants using the integrated monitoring will have their home blood pressure readings sent directly to their participating health systems. Participants using the manual monitoring will record their own blood pressures and report them to their health care system as per usual care.
The investigators hypothesize that remote monitoring (both integrated and manual) will be associated with improved blood pressure control and that there will be no difference in control between type of remote monitoring.
Aim 1: Evaluate whether this remote blood pressure quality improvement initiative leads to improved blood pressure control.
Aim 2: Compare the impact of integrated versus manual remote monitoring on blood pressure control.
The primary outcome measures will be: 1) the difference in blood pressure after six months (adjusted for baseline variables), and 2) whether participants achieved greater than or equal to 5 mmHg change in systolic blood pressure (SBP).
Outcomes will be compared between participants in each arm to determine whether one type of monitoring is superior to the other.
The investigators will convene bi-monthly meetings with site champions to foster communication and learning across sites and to learn about variation across sites.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Davis, California, United States, 95616
- University of California, Davis
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 years and older.
- Participant must be willing and functionally able (with help from another person if needed) to both use the remote BP monitoring device as well as do home BP monitoring using a manual BP cuff.
Have access to the online healthcare portal (with help from another person if needed).
•-Have outpatient visit within the last 12 months, and have a prior visit within 6 months of inclusion outpatient visit with diagnosis of hypertension, defined as having two readings of SBP > 140 or DBP > 90 mmHg
- Has visit with a primary care physician within one year.
- Takes zero or three anti-hypertensive prescriptions (can include pills with 2 different drugs so could be on 2 medications).
Exclusion Criteria:
- BP > 180/110 mmHg (office) or > 175/105 mmHg (self-measured BP measurements)
- Pheochromocytoma
- Uncontrolled hypothyroidism or hyperthyroidism
- Renal artery stenosis
- Conn's syndrome
- End stage renal disease (ESRD)
- Chronic kidney disease (CKD) Stage 3b (CrCL < 45) and above
- Transplant patients --> used the code that if they ever had a transplant
- Pregnancy
- Severe aortic stenosis
- Hospice/End-of-life or Palliative Care
- Left Ventricular Ejection Fraction < 30%
- Acute cardiac event in the last 3 months (e.g. acute MI)
- Heart block and arrhythmia(s)
- Recurrent or symptomatic hypotension (SBP < 100 mmHg or DBP < 60 mmHg)
- Drug/alcohol abuse
- Orthostatic hypotension (drop in SBP >20 mmHg)
- Other secondary causes of hypertension
- Receiving hypertension management from other services (home health, hospice, already enrolled in hypertension management program)
- White coat hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Integrated
Participants will have their home blood pressure readings sent directly to their participating health systems.
Participants will also receive a wrap-around intervention.
|
Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program.
Data will be sent directly to their participating health system.
|
|
Active Comparator: Manual
Participants will record their own blood pressures and report them to their health care system as per usual care.
|
Patients will receive a standard blood pressure monitor and education on how to use it.
Data will be reported as part of usual care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Continuous change in blood pressure (BP)
Time Frame: Baseline, six months
|
the difference in systolic blood pressure after six months (adjusted for baseline variables)
|
Baseline, six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory pre-post analysis of overall change in BP
Time Frame: Baseline, six months
|
for all participants, subanalysis for select demographics including elderly.
|
Baseline, six months
|
|
Binary 5mm change in blood pressure
Time Frame: Baseline, six months
|
whether participants achieved greater than or equal to 5 mmHg change in systolic blood pressure
|
Baseline, six months
|
|
Binary measure of controlled vs uncontrolled hypertension
Time Frame: Baseline, six months
|
where uncontrolled is defined as SBP > 130 mmHg or diastolic blood pressure (DBP) > 80 mmHg.
|
Baseline, six months
|
|
Changes in blood pressure (BP) outcomes from integrated monitor readings
Time Frame: Baseline, six months
|
For participants in the integrated device study arm, we will calculate the change between the baseline BP and the latest BP reading that is recorded via the remote device.
|
Baseline, six months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: Baseline, six months
|
acute coronary syndrome, myocardial infarction, non-ST-elevation myocardial infarction (NSTEMI), ST Elevation Myocardial Infarction (STEMI), stroke (ischemic, hemorrhagic), decompensated heart failure, all-cause mortality, hospitalization, syncope, hyponatremia, hypokalemia, hyperkalemia
|
Baseline, six months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Catherine Sarkisian, MD, MSHS, Director, Value-Based Care Research Consortium
Publications and helpful links
General Publications
- Carey RM, Whelton PK. The 2017 American College of Cardiology/American Heart Association Hypertension Guideline: A Resource for Practicing Clinicians. Ann Intern Med. 2018 Mar 6;168(5):359-360. doi: 10.7326/M18-0025. Epub 2018 Jan 23. No abstract available.
- Shimbo D, Artinian NT, Basile JN, Krakoff LR, Margolis KL, Rakotz MK, Wozniak G; American Heart Association and the American Medical Association. Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association. Circulation. 2020 Jul 28;142(4):e42-e63. doi: 10.1161/CIR.0000000000000803. Epub 2020 Jun 22. Erratum In: Circulation. 2020 Jul 28;142(4):e64.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22000036
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.